Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Stock Price Drops 7.8 Percent On News of Stratagene Suit

NEW YORK, May 12 (GenomeWeb News) - The share price of Third Wave Technologies has fallen 7.8 percent, or $.31, as investors reacted warily to the news that the company is being sued by Stratagene for alleged infringement of two of that company's copyrights.

 

Stratagene said Third Wave's Invader technology infringed on two of the four patents behind its FullVelocity line of Q-PCR products mid-day on May 9. Third Wave's stock price stood at $4.26 when the market closed May 9, and has dropped to $3.95 in mid-after noon trading today.

 

Third Wave sued Stratagene in September, claiming that FullVelocity patents infringed on its Invader patents. That suit is ongoing.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.